Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 12:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: EGFR T790M Clear all
Terminated No phase listed Observational

TAURAS - T790 AURA ScreenFailure SOC Registry Study

NCT02405247
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Patient Reported Outcome (PRO)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Oceanside, California • Santa Rosa, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2015 · Synced Oct 25, 2026, 12:35 AM EDT
Completed Phase 2 Interventional Results available

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

NCT02094261
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
AZD9291
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
9
States / cities
La Jolla, California • Orange, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 25, 2026, 12:35 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

NCT02349633
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
PF-06747775, Palbociclib, Avelumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
La Jolla, California • San Diego, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 25, 2026, 12:35 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients

NCT03236675
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Not listed
Lead sponsor
Exosome Diagnostics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Hollywood, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 25, 2026, 12:35 AM EDT
Terminated Phase 2 Interventional

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

NCT02485652
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
HM61713
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
20 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
15
States / cities
Beverly Hills, California • Burbank, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 25, 2026, 12:35 AM EDT
Completed Phase 2 Interventional Results available

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

NCT02759835
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Neoplasms
Interventions
osimertinib, Local Ablative Therapy (LAT)
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 25, 2026, 12:35 AM EDT
Completed Phase 2 Interventional Results available

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

NCT01858389
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Dacomitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Beverly Hills, California • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 25, 2026, 12:35 AM EDT
Completed No phase listed Observational

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

NCT03137264
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Other
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
20
States / cities
Anaheim, California • Los Angeles, California • Santa Rosa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 25, 2026, 12:35 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

NCT01526928
View directory record Official record
Conditions
Locally Advanced or Metastatic Non Small Cell Lung Cancer
Interventions
Rociletinib
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
39
States / cities
Duarte, California • Fountain Valley, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 25, 2026, 12:35 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

NCT06706076
View directory record Official record
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed
Drug
Lead sponsor
BlossomHill Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
24
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 25, 2026, 12:35 AM EDT
Completed No phase listed Observational

Detecting EGFR T790M Mutations From Circulating Tumor Cells

NCT01734915
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Circulating tumor cell chip
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Oct 25, 2026, 12:35 AM EDT
Terminated Phase 1 Interventional

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer

NCT02448251
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
AC0010MA
Drug
Lead sponsor
ACEA Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Duarte, California • Palo Alto, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 25, 2026, 12:35 AM EDT
Terminated Phase 2 Interventional

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

NCT02454842
View directory record Official record
Conditions
Non-small Cell Lung Cancer, NSCLC, Non-squamous NSCLC
Interventions
TH-4000 (Tarloxotinib)
Drug
Lead sponsor
Rain Oncology Inc
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Santa Rosa, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 25, 2026, 12:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

AZD9291 First Time In Patients Ascending Dose Study

NCT01802632
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Interventions
AZD9291
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 25, 2026, 12:35 AM EDT
Terminated Phase 1 Interventional

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

NCT04862780
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, EGFR T790M, EGFR C797S, EGFR L858R, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, EGFR Exon 19 Deletion, EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance, EGFR Activating Mutation, Protein Kinase Inhibitors, Antineoplastic Agents, Thoracic Neoplasms
Interventions
BLU-945, osimertinib
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 25, 2026, 12:35 AM EDT
Not listed Phase 1Phase 2 Interventional

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

NCT05498389
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, EGFR Mutation-Related Tumors
Interventions
EMB-01, Osimertinib
Drug
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Orange, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 25, 2026, 12:35 AM EDT
Completed Phase 1 Interventional

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

NCT02113813
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations
Interventions
naquotinib, midazolam
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 25, 2026, 12:35 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

NCT06303167
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Osimertinib, Radiologic Examination
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 25, 2026, 12:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

NCT02108964
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer
Interventions
EGF816
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 25, 2026, 12:35 AM EDT
Completed Phase 3 Interventional Results available

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT02151981
View directory record Official record
Conditions
Anticancer Treatment
Interventions
Chemotherapy, Cross-over to Osimertinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
21
States / cities
Anaheim, California • Orange, California • Santa Rosa, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 25, 2026, 12:35 AM EDT
Completed Phase 1 Interventional Results available

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

NCT01999985
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer (NSCLC)
Interventions
Dasatinib - 1A, Afatinib - 1A, Dasatinib - 1B, Afatinib - 1B
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 25, 2026, 12:35 AM EDT
Active, not recruiting No phase listed Observational

INHERIT EGFR - Studying Germline EGFR Mutations

NCT01754025
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 12:35 AM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

NCT02323126
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
EGF816, INC280, Nivolumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 25, 2026, 12:35 AM EDT
Completed Phase 2 Interventional Results available

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

NCT02489903
View directory record Official record
Conditions
Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer
Interventions
RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
Palo Alto, California • West Haven, Connecticut • South Bend, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 25, 2026, 12:35 AM EDT